Ananda Pharma Plc (AQSE:ANA) has hit a key milestone in the development of MRX1, its cannabidiol-based medicine, by completing the final technical batch needed for regulatory approval.
This step is crucial for securing approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to begin clinical trials.
The company confirmed that MRX1 meets all required standards, including consistency and shelf-life, which are essential for regulatory approval not just in the UK but also in other markets, such as the United States.
Ananda CEO Melissa Sturgess said: "The detailed and intricate work to ensure our MRX1 CBD drug candidate meets the requirements for MHRA clinical trial approval is progressing well. These workstreams provide the foundations of Ananda's house and must be built properly."
The next step is to produce the first Good Manufacturing Practice (GMP) batch of MRX1, which will be used in upcoming clinical trials.
These trials include a study on chemotherapy-induced pain led by Professor Marie Fallon at Edinburgh University; an endometriosis clinical evaluation overseen by Dr Lucy Whitaker; and a pharmacokinetic assessment in Australia to assess how the drug is absorbed and processed in the body.